Abstract

Naltrexone is a competitive opioid receptor antagonist indicated to treat opioid and alcohol dependence. In the U.S., naltrexone is commercially available as 50-mg tablets, and the adult dosage strength typically ranges between 50 mg once daily and 100 mg once daily. However, there is evidence to suggest that naltrexone prescribed in low doses, about 1/10th of the daily standard dosage, may be effective in managing a myriad of chronic conditions, including pain refractory to conventional pharmacological treatments. The U.S. Food and Drug Administration recently granted an orphan drug designation for low-dose naltrexone for the treatment of complex regional pain syndrome. This article provides a case study of a patient who was treated with a low dose of naltrexone for pain associated with the diagnosis of idiopathic hypereosinophilic syndrome.

Related Keywords

• low-dose naltrexone
• formulation
• pain management
• complex regional pain syndrome
• case report
• idiopathic hypereosinophilic syndrome
• mepolizumab
• analgesia
• inflammation
• analgesic agent
• anti-inflammatory agent
• Neuropathic Pain Symptom Inventory
• NPSI
• dose titration
• dose increases
• patient assessment
• pain intensity

Related Categories

• FORMULATIONS
• PAIN MANAGEMENT
• CASE REPORTS
• PATIENT ASSESSMENT